Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43851   clinical trials with a EudraCT protocol, of which   7283   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-003205-15
    Sponsor's Protocol Code Number:GO29527
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2015-10-15
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2014-003205-15
    A.3Full title of the trial
    A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI?PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED
    CHEMOTHERAPY IN PD-L1?SELECTED PATIENTS WITH COMPLETELY RESECTED STAGE IB?IIIA NON?SMALL CELL LUNG CANCER
    ESTUDIO EN FASE III, ABIERTO Y ALEATORIZADO PARA INVESTIGAR LA EFICACIA Y SEGURIDAD DE ATEZOLIZUMAB ANTICUERPO ANTI-PD-L1) EN COMPARACIÓN CON EL TRATAMIENTO DE SOPORTE ÓPTIMO DESPUÉS DE QUIMIOTERAPIA ADYUVANTE BASADA EN CISPLATINO EN PACIENTES SELECCIONADOS POR PD-L1 CON CÁNCER DE PULMÓN NO MICROCÍTICO EN ESTADIO IB-IIIA TOTALMENTE RESECADO
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI?PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING LUNG CANCER RESECTION AND CHEMOTHERAPY FOR EARLY STAGE LUNG CANCER.
    Estudio Fase III, abierto y randomizado para investigar la eficacia y seguridad de Atezolizumab (anticuerpo Anti-PD-L1) comparado con el tratamiento de soporte optimo para pacientes con cáncer de pulmón en estadio inicial resecado y tras quimioterapia.
    A.4.1Sponsor's protocol code numberGO29527
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorF. Hoffmann-La Roche Ltd
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportF. Hoffmann-La Roche Ltd
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationF.Hoffmann-La Roche Ltd
    B.5.2Functional name of contact pointTrial Information Support Line-TISL
    B.5.3 Address:
    B.5.3.1Street AddressGrenzacherstrasse 124
    B.5.3.2Town/ cityBasel
    B.5.3.3Post code4070
    B.5.3.4CountrySwitzerland
    B.5.4Telephone number+34 91 325 73 00
    B.5.6E-mailglobal.rochegenentechtrials@roche.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMPDL3280A-RO5541267
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAtezolizumab
    D.3.9.2Current sponsor codeRO5541267
    D.3.9.3Other descriptive nameMPDL3280A
    D.3.9.4EV Substance CodeSUB126162
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number60
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    NON?SMALL CELL LUNG CANCER
    CÁNCER DE PULMÓN NO MICROCÍTICO
    E.1.1.1Medical condition in easily understood language
    NON?SMALL CELL LUNG CANCER
    CÁNCER DE PULMÓN NO MICROCÍTICO
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.1
    E.1.2Level LLT
    E.1.2Classification code 10029514
    E.1.2Term Non-small cell lung cancer NOS
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the efficacy of 16 cycles of atezolizumab treatment compared with best supportive care as measured by disease-free survival (DFS) as assessed by the investigator.
    Evaluar la eficacia de 16 ciclos de tratamiento con atezolizumab en comparación con el tratamiento de soporte óptimo (TSO), determinada mediante la supervivencia sin enfermedad (SSE) conforme a la evaluación del investigador.
    E.2.2Secondary objectives of the trial
    To evaluate the efficacy of 16 cycles of atezolizumab treatment compared with BSC as measured by OS
    Evaluar la eficacia de 16 ciclos de tratamiento con atezolizumab en comparación con el TSO, determinada mediante la SG.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    ?Tumor PD-L1 expression of TC3 or IC3, as determined by an IHC assay performed by a central laboratory on a resected tumor tissue previously obtained at screening. A representative formalin-fixed paraffin-embedded (FFPE) tumor specimen in paraffin block (preferred) or a minimum of 15 unstained, freshly cut, serial sections from an FFPE resected tumor specimen is required for participation in
    this study. This specimen must be accompanied by the associated pathology report.
    ?ECOG performance status of 0 or 1
    ?Histological or cytological diagnosis of Stage IB (tumors ? 4 cm)?IIIA (T2?3 N0, T1?3 N1, T1-3 N2) NSCLC
    ?Eligibility to receive a cisplatin-based chemotherapy regimen
    ?For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 90 days after the last dose of study drug
    - Expresión de PD-L1 en el tumor de CT3 o CI3, determinada mediante un análisis de IHQ realizado en un laboratorio central con tejido tumoral resecado obtenido anteriormente en la visita de selección. Para participar en este estudio se requiere una muestra tumoral representativa fijada con formol e incluida en parafina (FFIP) en un bloque de parafina (de elección) o un mínimo de 15 extensiones seriadas, de obtención reciente y sin teñir procedentes de una muestra de tumor resecado FFIP. Esta muestra deberá ir acompañada del informe anatomopatologico correspondiente.
    - Estado funcional del ECOG de 0 o 1.
    - Diagnóstico histológico o citológico de CPNM en estadio IB (tumores ? 4 cm)-IIIA (T2-3 N0, T1-3 N1, T1-3 N2)
    - Elegibilidad para recibir una pauta de quimioterapia basada en cisplatino.
    - Mujeres en edad fértil: compromiso de mantener la abstinencia (abstenerse de relaciones heterosexuales) o de utilizar uno o varios métodos anticonceptivos con un índice de fallos <1% al año durante el período de tratamiento y durante al menos 90 días después de la última dosis del fármaco del estudio
    E.4Principal exclusion criteria
    ? Pregnant and lactating women
    ?Treatment with prior systemic chemotherapy at any time
    Methotrexate given in low doses for non-malignant conditions with the last dose
    at least 14 days prior to date of enrollment will be allowed. Other low-dose
    chemotherapeutics for non-malignant conditions will be considered after
    discussion with and approval by the Medical Monitor
    ?Hormonal cancer therapy or radiation therapy as prior cancer treatment within 5 years before enrollment
    ?Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 28 days prior to enrollment
    ?Known sensitivity to any component of the chemotherapy regimen the patient will be assigned to, or to mannitol
    ?Prior treatment with an anti?PD-1, anti?PD-L1, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
    - Mujeres embarazadas o en periodo de lactancia.
    - Tratamiento previo con quimioterapia sistémica en cualquier momento. Se permitirá la administración de metotrexato en dosis bajas por enfermedades no neoplásicas siempre que la última dosis se haya administrado al menos 14 días antes de la fecha de inclusión. La administración de otros quimioterapicos en dosis bajas por enfermedades no neoplásicas se tendrá en cuenta tras consultar al monitor médico y obtener su aprobación.
    - Hormonoterapia antineoplásica o radioterapia como tratamiento previo del cáncer en los 5 años previos a la inclusión.
    - Tratamiento con otros fármacos en investigación o participación en otro estudio clínico con intención terapéutica en los 28 días previos a la inclusión.
    - Hipersensibilidad conocida a cualquiera de los componentes de la pauta de quimioterapia a la que será asignado el paciente o al manitol.
    - Tratamiento previo con anti-PD-1, anti-PD-L1, anti-CD137 o anticuerpos contra el antígeno 4 asociado a los linfocitos T citotoxicos (como ipilimumab o cualquier otro anticuerpo o fármaco que actué específicamente sobre la coestimulación de linfocitos T o vías de puntos de control inmunológico).
    E.5 End points
    E.5.1Primary end point(s)
    ?DFS, defined as the time from randomization to the date of occurrence of any of the following, whichever occurs first:
    First recurrence of NSCLC, as determined by the investigator after an
    integrated assessment of radiographic data, biopsy sample results (if available),
    and clinical status
    Occurrence of new primary NSCLC, as assessed by the investigator
    Death from any cause
    - SSE, definida como el tiempo transcurrido entre la aleatorización y la fecha de aparición de cualquiera de las situaciones siguientes, lo que ocurra antes:
    Primera recidiva del CPNM, según lo determinado por el investigador tras una evaluación integrada de los datos radiológicos, los resultados de las muestras de biopsia (si procede) y el estado clínico.
    Aparición de un nuevo CPNM primario, conforme a lo evaluado por el investigador.
    Muerte por cualquier causa.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Please refer to E.5.1
    Por favor, ver sección E.5.1.
    E.5.2Secondary end point(s)
    ?OS, defined as the time from randomization to death from any cause
    SG, definida como tiempo desde randomización hasta muerte por cualquier causa.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Please refer to E.5.2
    Por favor, ver sección E.5.2
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned18
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA119
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Belgium
    Canada
    China
    France
    Germany
    Hong Kong
    Hungary
    Israel
    Italy
    Japan
    Korea, Republic of
    Netherlands
    Poland
    Portugal
    Romania
    Russian Federation
    Spain
    Taiwan
    Ukraine
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study is defined as the latter of the dates of when 433 deaths have occurred in the global main study?s ITT population and 355 deaths have occurred in the Stage II?IIIA subpopulation.
    El final del estudio se define como la fecha en que se hayan producido 433 o 355 muertes en la población IT o la subpoblación en estadio II-IIIA, respectivamente, la que sea más tardía.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months5
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 592
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 245
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state27
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 346
    F.4.2.2In the whole clinical trial 845
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The Sponsor will evaluate the appropriateness of continuing to provide atezolizumab to patients assigned to the treatment arm after evaluating the primary efficacy outcome measure and safety data gathered in the study. These analyses may be conducted prior to completion of the study.
    El promotor valorará la conveniencia de seguir proporcionando atezolizumab a los pacientes asignados al grupo de tratamiento tras evaluar el criterio de valoración
    principales de la eficacia y los datos de seguridad recogidos en el estudio. Estos análisis podrán realizarse antes de la finalización del estudio.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-10-19
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-10-13
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 20 10:25:20 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA